Funds obtained willenable the European leader in cardiac safety to continue its development in Europe, North America and Asia
Nancy and Paris, France, March 10, 2020–Banook Group, a clinical research organization (CRO) specialized in cardiac safety, centralized analysesof medical imagery and event adjudication, announces today that it has obtained new investment from Turenne Santé, via the FPCI Capital Santé 2. Along with founder Pascal Voiriot and senior management representatives, including Alexandre Durand-Salmon, Turenne Santé has now become the main investor in Banook Group, with a view to developing the company both internationally and in France. Euro Capital, based in Metz, advised by Turenne Group, and the ILP funds, based in Nancy, have also invested.
Founded in 1999 by Pascal Voiriot and based in Nancy, France, the Banook Group has developed notable expertise in the evaluation of cardiac safety in drug development trials. Banook Group works with pharmaceutical and biotech companies, CROs, non-profit organizations and academic centers involved in phase 1-3 clinical trials, prior to new medication approval. The Banook Group helps companies that develop new ECG tracing recording devices to validate their algorithm. It also has expertise in the centralized analysisof medical imagery and the adjudication of major clinical events.
This transaction, led by Turenne Santé, marks the first step in a change in management with a capital contribution by senior managers Alexandre Durand-Salmon, Yasmin Khan and Stéphane Papelier. Alongside Pascal Voiriot, their ambition is to pursue the development of the group in Europe, where Banook Group already has a strong customer base, North America and Asia.The company is also aiming for ISO certification by the beginning of 2021. According to the group’s estimates, the cardiac safety and imaging segment represented around $140 million (€123M) in 2017. It is estimated that the global CRO market should represent nearly $44 billion (€39bn) in 2021.
Pascal Voiriot and Alexandre Durand-Salmon, respectively president and CEO of the Banook Group, said: “This operation is an important step in the acceleration of our development. The Banook Group places great importance in the improvement of the quality of life of millions of patients throughout the world. This is reflected in the company culture and our commitment to bringing science closer to people. We are excited to embark on this ambitious journey with our new partners.”
Benoit Pastour, CEO of the Turenne Group, and Paul Chamoulaud, associate director of Turenne Santé, said: “The Banook Group benefits from unique expertise in the field of cardiac safety, in which they are one of the leaders in Europe. Through this deal, the first step of the transition has been undertaken between Pascal Voiriot, the current president, and the senior management. We share their ambition to grow both in Europe and internationally. With this transaction, Capital Santé 2 achieves its third investment in less than a year.”
InvestorsTurenne Santé–Benoît Pastour, Paul Chamoulaud, Sophie CanetosEuro Capital–Charles-Henri BooterILP–Benoît Voinot
Legal advisors and auditLamartine Conseil–Gary Lévy, Raphaël Saulneron, SolangeDucos, Maeva Suire, Emilie Renaud,DianeDubail,Charlotte Moreau, PatriciaVolpe Financial audit advisorsNext!–Hervé Krissi, Laura Guerrin
Strategy audit advisorsCepton–Marc-Olivier Bévierre, Marine Mousseaux
Financial advisors vendorAdvisoPartners–Guillaume Capelle, Elisa Valdes, Baptiste Hoppenot
Financial advisors managementActa Finance–Jean-Denis Cornillot, Jacques-Henry Piot
Financial advisors othersAdvance–Arnaud Vergnole, Pierre Lamain
Legal advisors managementJuriact–Frédéric Ferry
Legal advisors vendorFidal–Didier Millot, Brice Voillequin, Loïc Toilier
Financial auditors vendorKPMG–Antoine Bernabeu, Joseph Aouad, Anne-MariamaSanou
Mezzanine debtIdinvest–Maxime de Roquette-Buisson, Audrey Silber
BankersLCL–Dirk Weinand, Aurélia BojmalBanque Populaire Alsace Lorraine Champagne–Lionel Werner, Olivier PetitfrereBanque Populaire Rives de Paris–Virginie Rojo y Pinto
About Turenne GroupWith more than €230M ($261M) under management, including more than €120M ($136M) raised for the FPCI Capital Santé 2, Turenne Santé supports healthcare companies in their development and transmission challenges.The Turenne Group, one of the leaders in private equity in France, has been supporting entrepreneurs for 20 yearsin their innovation and development projects, as well as the sale of their companies. As an independent player, the group managed €1bn ($1.14bn) as of December
About Banook Group
The Banook Group is one of the few international providers capable of supplying cardiac safety, central imaging and endpoint adjudication services to pharmaceutical groups, biotech companies, medical device manufacturers, CROs and nonprofit organizations.Its mission is to help its clients develop the healthcare of tomorrow, using high quality, reliable and innovative solutions in all phases of clinical trials and ultimately to bring new solutions to market for the benefit of patients.Its medical and regulatory expertise, quality-driven approach and team availability make the Banook Group a key player in clinical trial services.Founded in 1999, the Banook Group operates on an international scale, maintaining offices at its headquarters in Nancy, France, and in Montreal, Quebec, Canada.To learn more about the subsidiaries of the Banook Group (CardiaBase, Banook Central Imaging and Banook Inc.), visit the website.www.banookgroup.com www.banookgroup.com